AIDS Research and Treatment / 2012 / Article / Tab 1 / Review Article
Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future Table 1 Publications of pivotal studies of drugs for multidrug-resistant HIV.
Drug Abbreviated study title and duration Study treatment (
) and comparator (
) arms Journal and date of publication TORO 1 (24 wks) ENF + 3–5 drug OBT (328) versus 3–5 drug OBT (167) NEJM, May 2003 [14 ] TORO 2 (24 wks) ENF + 3–5 drug OBT (335) versus 3–5 drug OBT (169) NEJM, May 2003 [15 ] Enfuvirtide (ENF) TORO 1 and 2 48 wk efficacy ENF + OBT (661) versus OBT (334) JAIDS, December 2005 [16 ] 48 wk safety ENF + OBT (663) versus OBT (334) JAIDS, December 2005 [29 ] Tipranavir (TPV) RESIST (48 wks) TPV/r + OBT (746) versus CPI/r + OBT (737) Lancet, August 2006 [31 ] POWER 1 (24 wks) DRV/r in 1 of 4 doses + OBT (255) versus CPI/r + OBT (63) AIDS, February 2007 [37 ] Darunavir (DRV) POWER 2 (24 wks) DRV/r in 1 of 4 doses + OBT (225) versus CPI/r + OBT (53) AIDS, March 2007 [38 ] POWER 1 and 2 (48 wks) DRV/r 600/100 mg BID + OBT (110) versus CPI/r + OBT (120) Lancet, April 2007 [32 ] DUET 1 (24 wks) ETR + DRV/r + OBT (304) versus DRV/r + OBT (308) Lancet, July 2007 [33 ] Etravirine (ETR) DUET 2 (24 wks) ETR + DRV/r + OBT (295) versus DRV/r + OBT (296) Lancet, July 2007 [34 ] DUET 1 and 2 (48 wks) ETR + DRV/r + OBT (599) versus DRV/r + OBT (604) AIDS, November 2009 [39 ] Raltegravir (RAL) BENCHMRK 1 and 2 (48 wks) RAL + OBT (462) + OBT (237) NEJM, July 2008 [36 ] Maraviroc (MVC) MOTIVATE 1 and 2 (48 wks) MVC QD + OBT (414) versus MVC BID + OBT (426) versus OBT (209) NEJM, October 2008 [35 ]
OBT: optimized background therapy; CPI: comparator protease inhibitor; r: ritonavir; QD: once daily; BID: twice daily; NEJM: The New England Journal of Medicine; JAIDS: Journal of Acquired Immune Deficiency Syndromes.